Citations as recorded by:

1. Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes

Acta Pharmacol Sin, 2017, 38(1) p. 80

DOI: 10.1038/aps.2016.103

Citations as recorded by: Cross Ref PMC Google

2. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors

Diabetes Research and Clinical Practice, 2017, 130 p. 142

DOI: 10.1016/j.diabres.2017.05.018

Citations as recorded by: Cross Ref

3. Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice

Expert Review of Endocrinology & Metabolism, 2017, 12(3) p. 155

DOI: 10.1080/17446651.2017.1316192

Citations as recorded by: Cross Ref Google

4. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors

Year: 2017

Citations as recorded by: Google

5. Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China

Year: 2017

Citations as recorded by: Google

6. Pharmacogenetics and personalized treatment of type 2 diabetes mellitus

Int J Diabetes Dev Ctries, 2016, 36(4) p. 508

DOI: 10.1007/s13410-016-0517-2

Citations as recorded by: Cross Ref Google

7. Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients

Pharmacogenetics and Genomics, 2016, 26(4) p. 178

DOI: 10.1097/FPC.0000000000000204

Citations as recorded by: Cross Ref Google

8. Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes

Diabetes Technology & Therapeutics, 2016, 18(9) p. 586

DOI: 10.1089/dia.2015.0427

Citations as recorded by: Cross Ref Google

9. Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients.

Exp. Clin. Endocrinol. Diabetes, 2016, 124 p. 1

DOI: 1

Citations as recorded by: Google

10. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation

Year: 2016

Citations as recorded by: Google

11. Genetics of Type 2 Diabetes: From Candidate Genes to Genome-Wide Association Analysis

Year: 2016

Citations as recorded by: Google

12. Patient profiling in diabetes and role of canagliflozin

Pharmgenomics Pers Med, 2014, 7 p. 367

DOI: 10.2147/52761.S0

Citations as recorded by: PMC Google

13. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China

Diabetologia, 2014, 57(4) p. 746

DOI: 10.1007/s00125-013-3146-z

Citations as recorded by: Cross Ref Google

14. Personalized medicine in Type 2 Diabetes

BioMed, 2014, 4(2)

DOI: 10.7603/s40681-014-0008-z

Citations as recorded by: Cross Ref PMC Google

15. The genetic architecture of type 2 diabetes pharmacotherapy: the emerging genomic evidence

Year: 2014

Citations as recorded by: Google

16. Pharmacogenetics and personalized treatment of type 2 diabetes

Biochem Med (Zagreb), 2013, 23 p. 154

DOI: 10.11613/BM.2013.020

Citations as recorded by: PMC Google

17. Pharmacogenetic variation and metformin response.

Curr. Drug Metab., 2013, 14 p. 1

Citations as recorded by: Google

18. From genotype to human β cell phenotype and beyond

Islets, 2012, 4(5) p. 323

DOI: 10.4161/isl.22282

Citations as recorded by: Cross Ref PMC Google

19. Research Highlights: Highlights from the latest articles in pharmacogenomics of oral antidiabetic drugs

Pharmacogenomics, 2012, 13(12) p. 1329

DOI: 10.2217/pgs.12.115

Citations as recorded by: Cross Ref

20. KCNQ1 基因在 2 型糖尿病领域的研究进展

Year: 2012

Citations as recorded by: Google